Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a preliminary performance summary for the fiscal year 2025, indicating a revenue increase and significant growth in net profit, driven by various product sales and investment income [1] Financial Performance - The company achieved an operating revenue of 1.516 billion yuan, representing a year-on-year growth of 7.26% [1] - The net profit attributable to the parent company was 241 million yuan, showing a year-on-year increase of 46.95% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 130 million yuan, reflecting a year-on-year decline of 6.01% [1] Asset and Equity Growth - At the end of the reporting period, the total assets of the company reached 3.053 billion yuan, marking a year-on-year growth of 24.11% [1] - The equity attributable to the parent company was 2.046 billion yuan, which is a year-on-year increase of 13.44% [1] Revenue Drivers - The growth in operating revenue was primarily due to increased sales of formulation products, raw materials, intermediates, and technical service income [1] - The increase in net profit attributable to the parent company was mainly influenced by investment income [1] - The decline in net profit after deducting non-recurring gains and losses was attributed to the accrual of equity incentive expenses; excluding this impact, the adjusted net profit was 182 million yuan, which is a 31.57% increase compared to the same period last year [1]

证券代码：688799 证券简称：华纳药厂 公告编号：2026-005 2、以上财务数据及指标以合并报表数据填制，但未经审计，最终结果以公司 2025 年年 度报告为准。 3、以上增减变动幅度数据如有尾差，系四舍五入所致。 二、经营业绩和财务状况情况说明 湖南华纳大药厂股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以湖南华纳大药厂股份有限公司（以下简称"公司"）2025年年度报告 为准，提请投资者注意投资风险。 | | 单位：万元 | | | | --- | --- | --- | --- | | 项目 | 本报告期 增减变动幅度（％） | 上年同期 | | | 营业总收入 | 151,559.43 7.26 | 141,294.92 | | | 营业利润 | 24,513.09 51.53 | 16,176.58 | | | 利润总额 | 24,554.73 51.88 | 16,167.63 | ...

南财智讯2月13日电，华纳药厂发布2025年度业绩快报，报告期内公司实现营业收入15.16亿元，同比增 长7.26%；归属于上市公司股东的净利润2.41亿元，同比增长46.95%；基本每股收益1.84元，同比增长 47.20%。 ...

Core Viewpoint - Hunan Warner Pharmaceutical Co., Ltd. has participated in the national organized procurement of drugs and has announced that several of its products are proposed to be selected for the continuation of procurement after the expiration of the previous agreement [1][3]. Group 1: Proposed Selected Products - The company has a total of 12 products proposed for selection in this procurement process [3]. - The procurement cycle for the selected products will last until December 31, 2028, starting from the actual execution date of the selection results [2]. Group 2: Financial Impact - The projected sales revenue from the selected products is estimated to be 176.18 million yuan for 2024, accounting for 12.47% of the company's total revenue for that year [3]. - For the period from January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [3]. - The selected products are expected to enhance the company's market share and brand influence as medical institutions will prioritize these products during the procurement cycle [3].

Group 1 - Fuda Alloy's controlling shareholder Wang Dawu plans to reduce his stake by up to 3% of the company's total shares, amounting to a maximum of 406.34 million shares, due to personal funding needs [1] - ST Songfa's subsidiary signed contracts for the construction of 17 vessels, with a total contract value between 1.6 billion to 1.8 billion USD [2] - Pairui Co. signed a technical cooperation agreement with a university to develop large-capacity power semiconductor devices and related power electronic modules, effective for three years [3] Group 2 - Shuangliang Energy indirectly participates in commercial aerospace projects, supplying heat exchangers for SpaceX's fuel production system, with orders totaling approximately 1.39 million CNY [4] - Hangya Technology plans to issue convertible bonds to raise up to 600 million CNY for various projects, including an intelligent manufacturing base in Malaysia [5] - Yuhua Development is publicly selling assets with a base price of 251 million CNY for residential properties [6] Group 3 - Penghui Energy plans to invest 2.1 billion CNY in a new battery production project in Zhengyang County, Henan Province, focusing on high-performance battery products [7] - Haige Communication's shareholder Yang Haizhou intends to reduce his stake by up to 0.1624% of the company's total shares [8] - Yaoshi Technology's controlling shareholder pledged 5.13% of shares to repay loans, with a pledge period from February 10, 2026, to February 2, 2027 [9][10] Group 4 - Hanyu Pharmaceutical received FDA approval for its drug Acetate Glatiramer Injection, used for treating relapsing multiple sclerosis [11] - Baiyao Tai's GoliMab Injection received EMA approval for various indications, including rheumatoid arthritis and ulcerative colitis [12] - Jiangxi Tungsten Equipment plans to issue A-shares to raise up to 1.882 billion CNY for acquisitions [13] Group 5 - Hesong New Materials expects to recognize asset impairment provisions between 23.6 million to 28.5 million CNY for 2025 [14] - ST Meichen's subsidiary is involved in two major lawsuits with a total amount of approximately 31.9 million CNY [15] - China Coal Energy reported a 7.3% year-on-year decline in coal sales for January 2026, with total sales of 20.05 million tons [16] Group 6 - Yida Co. plans to adjust its epoxy propylene derivative project, reducing the total investment from 845 million CNY to 642 million CNY [17] - Fosun Pharma's subsidiary received approval for a clinical trial of HLX15-SC for multiple myeloma treatment [18][19] - Yinfeng Communication's board members and executives have terminated their share reduction plan [20] Group 7 - Huazhong High-tech has waived its preferential purchase rights for a fund, extending the investment period from three to four years [21] - Warner Pharmaceuticals plans to participate in a national drug procurement program, with expected sales of 176 million CNY [22] - Changling Hydraulic announced a tender offer to acquire 12% of its shares at a price of 35.82 CNY per share [23] Group 8 - ST Chuan Zhi's stock may face delisting due to financial data falling below regulatory thresholds [24] - Tian Pharmaceutical and its subsidiaries are participating in a national drug procurement program, with expected sales of 323 million CNY [25] - China Metallurgical Group signed new contracts worth 73.65 billion CNY in January 2026 [26] Group 9 - Torus plans to invest 21.2 million CNY in a venture capital fund focused on artificial intelligence [27] - Shangwei Co. received a government subsidy of 1.764 million CNY, representing 10.79% of its net profit for 2024 [28] - Hanghua Co. reported a 21.97% decline in net profit for 2025, with total revenue of 1.249 billion CNY [29] Group 10 - Huaxia Bank reported a 1.72% decline in net profit for 2025, with total revenue of 91.914 billion CNY [30] - Guotou Fengle plans to transfer 51% of its stake in Hubei Fengle Ecological Fertilizer to optimize management [31] - Huaru Technology is co-investing in a fund with a total commitment of 20 million CNY [32] Group 11 - Jindike reported a loss of 173 million CNY for 2025, despite a 40.13% increase in revenue [33] - Zhenong Co. announced a 0.52% increase in shares held by a major shareholder [34] - Maike Audi plans to recognize asset impairment provisions of approximately 52.55 million CNY [35] Group 12 - Fuan Pharmaceutical's subsidiary is expected to be selected for a national drug procurement program, with projected sales of 680 million CNY [36] - Rundu Co. is participating in a national drug procurement program, with some products expected to be selected [37] - Changqing Co. has postponed its large-scale die-casting project to March 2027 due to customer requirements [38] Group 13 - Pan Asia Micro透 received a patent for a graphene-based automotive headlight defogging device [39] - Luan An Huan Neng reported a 17.1% increase in raw coal production for January 2026, totaling 5 million tons [40] - Guangji Pharmaceutical received a drug registration certificate for Mecobalamin Tablets [41] Group 14 - Ruifeng New Materials announced the resignation of its deputy general manager for personal reasons [42] - Zhiguang Electric's subsidiary signed a procurement contract for energy storage equipment worth 210.4 million CNY [43] - Youyan Powder Materials reported a 19.41% increase in net profit for 2025 [44] Group 15 - Jincheng reported a 22.2% increase in net profit for 2025, with total revenue of 253 million CNY [46]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has announced its participation in the national organized procurement for drugs whose agreements have expired, with several of its products, including montmorillonite powder, being proposed for selection in this procurement process [1] Group 1: Procurement Results - The company has a total of 12 products proposed for selection in the recent procurement [1] - The expected sales revenue from these selected products for 2024 is 176.18 million yuan, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 2: Market Impact - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed procurement volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and promote the domestic market development of the company's products [1] - This development is expected to enhance the company's brand influence in the market [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has announced its participation in the national organized procurement for drugs whose agreements have expired, with several of its products, including Montmorillonite Powder, being proposed for selection in this procurement [1] Group 1: Procurement Results - The company has a total of 12 products proposed for selection in the recent procurement [1] - The expected sales revenue from these selected products for 2024 is 176.18 million yuan, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 2: Market Impact - During the procurement cycle, medical institutions will prioritize the use of the selected drugs, ensuring the completion of the agreed procurement volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and promote the domestic market development of the company's products [1] - This development is expected to enhance the company's brand influence in the market [1]

证券代码：688799 证券简称：华纳药厂 公告编号：2026-004 湖南华纳大药厂股份有限公司 自愿披露关于公司参与国家组织集采药品协议期满 品种接续采购拟中选的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 注 1：上述产品最终中选结果、中选价格等以接续采购办公室发布的最终数据为准。 注 2：本次拟中选药品的采购周期为自中选结果实际执行日起至 2028 年 12 月 31 日。 二、本次拟中选产品对公司的影响 本次接续采购品种为第 1-8 批国家组织集采协议期满的品种，约定采购量以 医药机构填报各企业采购品种需求量为基数，按照中选价格梯度确定带量比例。 采购周期自中选结果实际执行日起至 2028 年 12 月 31 日。 公司本次拟中选的产品共计 12 个。公司上述拟中选产品 2024 年实现销售收 入为 17,618.05 万元，占公司 2024 年营业收入的 12.47%；2025 年 1-9 月实现销 售收入为 19,205.12 万元，占公司 2025 年 1-9 月营业收入的 17.69%。采购周期 中 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has participated in the national organized procurement for drugs whose agreements have expired, with several of its products expected to be selected in this procurement process [1] Group 1: Procurement Details - The procurement involves products from the first to the eighth batch of national organized procurement agreements that have expired, with the purchasing volume based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual implementation date of the selected results [1] Group 2: Financial Impact - A total of 12 products from the company are expected to be selected, with projected sales revenue of 176.18 million yuan for 2024, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 3: Market Implications - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed purchasing volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and enhance the company's brand influence in the domestic market [1]

Core Viewpoint - Warner Pharmaceuticals (688799) has announced its participation in the national organized procurement for drugs whose agreements have expired, with 12 products expected to be selected for the continuation of procurement [2] Group 1: Financial Impact - The expected sales revenue from the selected products for 2024 is 176 million yuan, accounting for 12.47% of the company's total revenue for that year [2] - For the period of January to September 2025, the anticipated sales revenue is 192 million yuan, representing 17.69% of the company's revenue for that period [2]